Scarica l'app Stockscreener
17.77
3.27%
-0.60
Dopo l'orario di chiusura:
17.95
0.18
+1.01%
Precedente Chiudi:
$18.37
Aprire:
$18.9
Volume 24 ore:
1.86M
Relative Volume:
2.01
Capitalizzazione di mercato:
$1.22B
Reddito:
$161.10M
Utile/perdita netta:
$-308.60M
Rapporto P/E:
-3.8051
EPS:
-4.67
Flusso di cassa netto:
$-259.90M
1 W Prestazione:
-2.95%
1M Prestazione:
-4.31%
6M Prestazione:
-29.29%
1 anno Prestazione:
-62.75%
Intervallo 1D:
$17.34
$19.05
Intervallo di 1 settimana:
$17.34
$20.38
Portata 52W:
$16.61
$51.51
Arvinas Inc Stock (ARVN) Company Profile
Nome
Arvinas Inc
Settore
Industria
Telefono
203-535-1456
Indirizzo
395 WINCHESTER AVE, NEW HAVEN, CT
Confronta ARVN con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARVN
Arvinas Inc
|
17.77 | 1.22B | 161.10M | -308.60M | -259.90M | -4.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
484.24 | 124.35B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
700.33 | 76.56B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
644.48 | 39.16B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
250.59 | 32.44B | 2.25B | -278.16M | -42.59M | -2.17 |
|
BNTX
Biontech Se Adr
|
120.01 | 28.77B | 3.30B | -501.07M | 1.03B | -2.1146 |
Arvinas Inc Stock (ARVN) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-12-10 | Iniziato | BTIG Research | Buy |
| 2024-11-18 | Iniziato | Stephens | Overweight |
| 2024-02-28 | Reiterato | Oppenheimer | Outperform |
| 2024-02-14 | Downgrade | Citigroup | Buy → Neutral |
| 2024-02-01 | Iniziato | Goldman | Buy |
| 2023-12-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2023-12-06 | Aggiornamento | Jefferies | Hold → Buy |
| 2023-11-20 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2023-10-23 | Aggiornamento | Wedbush | Neutral → Outperform |
| 2023-06-26 | Ripresa | Oppenheimer | Outperform |
| 2023-01-12 | Downgrade | Guggenheim | Buy → Neutral |
| 2023-01-03 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2022-09-09 | Iniziato | Barclays | Overweight |
| 2022-06-21 | Iniziato | Jefferies | Hold |
| 2022-05-09 | Downgrade | Wedbush | Outperform → Neutral |
| 2022-04-28 | Iniziato | Credit Suisse | Outperform |
| 2022-04-06 | Iniziato | Morgan Stanley | Equal-Weight |
| 2022-02-11 | Ripresa | BMO Capital Markets | Outperform |
| 2022-02-10 | Iniziato | Wells Fargo | Overweight |
| 2022-01-19 | Iniziato | Goldman | Buy |
| 2021-12-07 | Iniziato | Cowen | Outperform |
| 2021-10-14 | Iniziato | SVB Leerink | Outperform |
| 2021-09-30 | Iniziato | Stifel | Buy |
| 2021-09-09 | Iniziato | BofA Securities | Buy |
| 2021-05-21 | Iniziato | UBS | Buy |
| 2021-04-21 | Iniziato | Truist | Buy |
| 2021-03-31 | Iniziato | BMO Capital Markets | Outperform |
| 2020-12-14 | Aggiornamento | Oppenheimer | Perform → Outperform |
| 2020-06-01 | Aggiornamento | Citigroup | Neutral → Buy |
| 2020-05-12 | Iniziato | Oppenheimer | Perform |
| 2019-12-19 | Iniziato | H.C. Wainwright | Buy |
| 2019-11-25 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Aggiornamento | Goldman | Neutral → Buy |
| 2019-09-25 | Iniziato | Wedbush | Outperform |
| 2019-09-12 | Iniziato | BMO Capital Markets | Outperform |
| 2019-08-06 | Iniziato | Cantor Fitzgerald | Overweight |
| 2019-06-05 | Downgrade | Citigroup | Buy → Neutral |
| 2019-04-12 | Iniziato | Evercore ISI | Outperform |
| 2018-10-22 | Iniziato | Citigroup | Buy |
| 2018-10-22 | Iniziato | Goldman | Neutral |
| 2018-10-22 | Iniziato | Piper Jaffray | Overweight |
Mostra tutto
Arvinas Inc Borsa (ARVN) Ultime notizie
Arvinas (NASDAQ:ARVN) shareholders have endured a 72% loss from investing in the stock three years ago - Yahoo Finance
Arvinas (ARVN) to Release Quarterly Earnings on Tuesday - MarketBeat
Arvinas (NASDAQ:ARVN) Shares Up 7.4%Time to Buy? - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Sees Significant Growth in Short Interest - MarketBeat
Arvinas Operations describes new DGK-α inhibitors - BioWorld Online
Equities Analysts Offer Predictions for Arvinas Q3 Earnings - MarketBeat
Wedbush Estimates Arvinas' Q1 Earnings (NASDAQ:ARVN) - MarketBeat
Earnings call transcript: Arvinas Q4 2024 surpasses EPS forecast, stock rises - Investing.com Nigeria
Q1 Earnings Forecast for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Given Average Recommendation of "Buy" by Analysts - MarketBeat
Oppenheimer Forecasts Strong Price Appreciation for Arvinas (NASDAQ:ARVN) Stock - MarketBeat
Arvinas (NASDAQ:ARVN) Receives Buy Rating from Guggenheim - MarketBeat
Analysts Offer Predictions for Arvinas FY2029 Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Stock Price Up 5% Following Better-Than-Expected Earnings - MarketBeat
Arvinas (NASDAQ:ARVN) Given "Outperform" Rating at BMO Capital Markets - MarketBeat
Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price - MarketBeat
Wedbush Reiterates Outperform Rating for Arvinas (NASDAQ:ARVN) - MarketBeat
How the (ARVN) price action is used to our Advantage - Stock Traders Daily
Arvinas anticipates Phase 3 topline results for vepdegestrant in Q1 2025 with commercial preparations underway - MSN
Arvinas (NASDAQ:ARVN) Posts Quarterly Earnings Results, Beats Estimates By $0.44 EPS - MarketBeat
How Much Upside is Left in Arvinas (ARVN)? Wall Street Analysts Think 235.09% - MSN
All You Need to Know About Arvinas (ARVN) Rating Upgrade to Buy - MSN
Arvinas Holding: Positive Earnings Call Highlights Growth - TipRanks
Q1 Earnings Estimate for Arvinas Issued By Leerink Partnrs - MarketBeat
Arvinas, Inc. (NASDAQ:ARVN) Q4 2024 Earnings Call Transcript - MSN
Arvinas Holding Faces Legal Risks Amid Stock Price Volatility - MSN
These Analysts Revise Their Forecasts On Arvinas After Q4 Results - Benzinga
Snowflake To Rally Around 9%? Here Are 10 Top Analyst Forecasts For Wednesday - Benzinga
Oppenheimer Adjusts Price Target on Arvinas to $45 From $40, Keeps Outperform Rating - Marketscreener.com
Arvinas Holding Company Receives ‘Buy’ Rating: Promising Clinical Advances and Strategic Pipeline Developments - TipRanks
Arvinas, Inc. (ARVN) Reports Q4 Loss, Misses Revenue Estimates - MSN
Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... By GuruFocus - Investing.com Canada
Arvinas (ARVN) to Release Earnings on Tuesday - MarketBeat
Arvinas Inc (ARVN) Q4 2024 Earnings Call Highlights: Strong Financial Position and Promising ... - Yahoo Finance
Arvinas Reports 2024 Financial Results and Pipeline Progress - TipRanks
Arvinas Inc. (ARVN) reports earnings - Quartz
ARVINAS, INC. SEC 10-K Report - TradingView
Arvinas Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update - GlobeNewswire
Arvinas, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2024 - Marketscreener.com
Arvinas Inc Azioni (ARVN) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Arvinas Inc Azioni (ARVN) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Houston John G | President and CEO |
Feb 23 '24 |
Sale |
47.05 |
5,196 |
244,472 |
1,036,681 |
| Cassidy Sean A | Chief Financial Officer |
Feb 23 '24 |
Sale |
47.05 |
1,702 |
80,079 |
181,916 |
| Peck Ronald | Chief Medical Officer |
Feb 23 '24 |
Sale |
47.05 |
1,699 |
79,938 |
67,516 |
| Taylor Ian | Chief Scientific Officer |
Feb 23 '24 |
Sale |
47.05 |
1,701 |
80,032 |
147,522 |
0.27%
3.05%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):